CN Patent

CN113337604A — 循环核酸肿瘤标志物的鉴别和用途

Assigned to Leland Stanford Junior University · Expires 2021-09-03 · 5y expired

What this patent protects

提供一些方法用于制备突变的基因组区域的选择子，并用于采用选择子集合来分析在无细胞核酸样品中的基因变异。所述方法可用于测量受试者血液样品中来源于肿瘤的核酸，并因此用于监控受试者疾病的进展，所述方法也可用于癌症筛查、癌症诊断、癌症预测和癌症疗法设计。

USPTO Abstract

提供一些方法用于制备突变的基因组区域的选择子，并用于采用选择子集合来分析在无细胞核酸样品中的基因变异。所述方法可用于测量受试者血液样品中来源于肿瘤的核酸，并因此用于监控受试者疾病的进展，所述方法也可用于癌症筛查、癌症诊断、癌症预测和癌症疗法设计。

Drugs covered by this patent

larotrectinib-sulfate (LAROTRECTINIB SULFATE)

Patent Metadata

Patent number: CN113337604A
Jurisdiction: CN
Classification: —
Expires: 2021-09-03
Drug substance claim: No
Drug product claim: No
Assignee: Leland Stanford Junior University
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.